JMJD3 Suppresses Tumor Progression in Oral Tongue Squamous Cell Carcinoma Patients Receiving Surgical Resection

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 Jul 20

PMID 35855897

Authors

Yen-Hao Chen

Chang-Han Chen

Chih-Yen Chien

Yan-Ye Su

Sheng-Dean Luo

Shau-Hsuan Li

Affiliations

Soon will be listed here.

Abstract

Background: Jumonji domain-containing-3 (JMJD3) is reported to be a histone H3 lysine 27 (H3K27) demethylase and a tumor suppressor gene. The present study designed to investigate the crucial role of JMJD3 in oral tongue squamous cell carcinoma (OTSCC) patients who received surgical resection.

Methods: We enrolled a total of 156 OTSCC patients receiving surgical resection, including 73 patients (47%) with high expression of JMJD3 and 83 patients (53%) harboring low expression of JMJD3. Two OTSCC cell lines, SAS and Cal 27, were used to explore the modulation of cancer. GSK-J4, a potent inhibitor of JMJD3, was used to treat the two OTSCC cell lines. The Chi-square test was performed to examine between-group differences in categorical variables; the Kaplan-Meier method was used to investigate survival outcome in univariate analysis, and the Cox regression model was used for multivariate analysis.

Results: The median follow-up period was 59.2 months and he five-year disease-free survival (DFS) and overall survival (OS) rates were 46.2% and 50.0%, respectively. Better five-year DFS (59% versus 35%) and five-year OS (63% versus 39%) were mentioned in patients with high expression of JMJD3 compared to those with low expression of JMJD3. High expression of JMJD3 was significantly associated with superior DFS and OS in the univariate and multivariate analyses. Following successful inhibition of JMJD3 by GSK-J4, western blotting analysis showed the decreased expression of Rb and p21.

Conclusion: Our study showed that high expression of JMJD3 is a good prognostic factor in OTSCC patients who underwent surgical resection.

Citing Articles

The Histone Demethylase Inhibitor GSK-J4 Attenuates Periodontal Bone Loss and Inflammation in a Rat Model of Periodontitis.

Kang J, Yu H, Xiang X, Ma Y, Zhang L, Zhang Y Curr Med Sci. 2025; .

PMID: 40048054 DOI: 10.1007/s11596-025-00018-2.

References

Zhang F, Xu L, Xu L, Xu Q, Li D, Yang Y . JMJD3 promotes chondrocyte proliferation and hypertrophy during endochondral bone formation in mice. J Mol Cell Biol. 2015; 7(1):23-34. PMC: 4342687. DOI: 10.1093/jmcb/mjv003. View

Ngollo M, Dagdemir A, Judes G, Kemeny J, Penault-Llorca F, Boiteux J . Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS. 2014; 18(3):207-9. DOI: 10.1089/omi.2013.0117. View

Ngollo M, Lebert A, Dagdemir A, Judes G, Karsli-Ceppioglu S, Daures M . The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer. 2014; 14:994. PMC: 4364597. DOI: 10.1186/1471-2407-14-994. View

Liang S, Yao Q, Wei D, Liu M, Geng F, Wang Q . KDM6B promotes ovarian cancer cell migration and invasion by induced transforming growth factor-β1 expression. J Cell Biochem. 2018; 120(1):493-506. DOI: 10.1002/jcb.27405. View

Pereira F, Barbachano A, Silva J, Bonilla F, Campbell M, Munoz A . KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet. 2011; 20(23):4655-65. DOI: 10.1093/hmg/ddr399. View

Park W, Hong B, Lee J, Choi C, Kim M . H3K27 Demethylase JMJD3 Employs the NF-κB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis. Cancer Res. 2016; 76(1):161-70. DOI: 10.1158/0008-5472.CAN-15-0536. View

Agger K, Cloos P, Christensen J, Pasini D, Rose S, Rappsilber J . UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007; 449(7163):731-4. DOI: 10.1038/nature06145. View

Cheng J, Diao P, Wang D, Zhang W, Jiang H, Wang Y . Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br J Cancer. 2019; 122(4):528-538. PMC: 7028736. DOI: 10.1038/s41416-019-0680-6. View

Ramadoss S, Chen X, Wang C . Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J Biol Chem. 2012; 287(53):44508-17. PMC: 3531764. DOI: 10.1074/jbc.M112.424903. View

10.

Sanchez A, Houfaf Khoufaf F, Idrissou M, Penault-Llorca F, Bignon Y, Guy L . The Functions of the Demethylase JMJD3 in Cancer. Int J Mol Sci. 2021; 22(2). PMC: 7835890. DOI: 10.3390/ijms22020968. View

11.

Sherr C, McCormick F . The RB and p53 pathways in cancer. Cancer Cell. 2002; 2(2):103-12. DOI: 10.1016/s1535-6108(02)00102-2. View

12.

Tokunaga R, Sakamoto Y, Nakagawa S, Miyake K, Izumi D, Kosumi K . The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer. Ann Surg Oncol. 2015; 23(2):678-85. DOI: 10.1245/s10434-015-4879-3. View

13.

Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A . Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer. 2012; 12:470. PMC: 3520868. DOI: 10.1186/1471-2407-12-470. View

14.

Zhang Y, Hua P, Jin C, Li J, Zhang G, Wang B . JMJD3 enhances invasiveness and migratory capacity of non-small cell lung cancer cell via activating EMT signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(11):4784-4792. DOI: 10.26355/eurrev_201906_18063. View

15.

Zhao W, Li Q, Ayers S, Gu Y, Shi Z, Zhu Q . Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell. 2013; 152(5):1037-50. PMC: 3742052. DOI: 10.1016/j.cell.2013.02.006. View

16.

Tian C, Deng H, Tang X, Hu H, Liu X, Luo F . [Effect of Jumonji domain-containing protein-3 on the proliferation and migration of lung cancer cell line]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2012; 29(3):514-8. View

17.

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

18.

Li Q, Hou L, Ding G, Li Y, Wang J, Qian B . KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. Int J Clin Exp Pathol. 2015; 8(6):6334-44. PMC: 4525843. View

19.

Zhao L, Zhang Y, Gao Y, Geng P, Lu Y, Liu X . JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein. Cell Death Differ. 2015; 22(10):1630-40. PMC: 4563788. DOI: 10.1038/cdd.2015.6. View

20.

Ohguchi H, Harada T, Sagawa M, Kikuchi S, Tai Y, Richardson P . KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia. 2017; 31(12):2661-2669. PMC: 5681448. DOI: 10.1038/leu.2017.141. View